David Barros Aguirre (David Barros-Aguirre, David Barros)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 28

Top Venues

Antimicrobial agents and chemotherapy

Nature medicine

Journal of medicinal chemistry

ACS infectious diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Si-Yang Li, Sandeep Tyagi, Heena Soni, Fabrice Betoudji, Paul J Converse, Khisimuzi Mdluli, Anna M Upton, Nader Fotouhi, David Barros Aguirre, Lluís Ballell, Elena Jimenez-Navarro, Eric L Nuermberger
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrobial agents and chemotherapy 68 (4) (2024)
Si-Yang Li, Sandeep Tyagi, Heena Soni, Fabrice Betoudji, Paul J Converse, Khisimuzi Mdluli, Anna M Upton, Nader Fotouhi, David Barros Aguirre, Lluís Ballell, Elena Jimenez-Navarro, Eric L Nuermberger
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrobial agents and chemotherapy (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Si-Yang Li, Sandeep Tyagi, Heena Soni, Fabrice Betoudji, Paul J Converse, Khisimuzi Mdluli, Anna M Upton, Nader Fotouhi, David Barros Aguirre, Lluís Ballell, Elena Jimenez-Navarro, Eric L Nuermberger
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrobial agents and chemotherapy 68 (4) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Si-Yang Li, Sandeep Tyagi, Heena Soni, Fabrice Betoudji, Paul J Converse, Khisimuzi Mdluli, Anna M Upton, Nader Fotouhi, David Barros Aguirre, Lluís Ballell, Elena Jimenez-Navarro, Eric L Nuermberger
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrobial agents and chemotherapy 68 (4) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy 67 (2) (2023)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy 67 (2) (2023)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy (2023)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy 67 (2) (2023)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy 67 (2) (2023)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy 67 (2) (2023)
Dereje Abate Negatu, Rubén González Del Río, Mónica Cacho, David Barros Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Veronique Anne Dartois, Thomas Dick
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. Antimicrobial agents and chemotherapy 67 (2) (2023)
Marion Flipo, Rosangela Frita, Marilyne Bourotte, María Santos Martínez, Markus Boesche, Gary W Boyle, Geo Derimanov, Gerard Drewes, Pablo Gamallo, Sonja Ghidelli-Disse, Stephanie Gresham, Elena Jiménez, Jaime de Mercado, Esther Pérez-Herrán, Esther Porras-De Francisco, Joaquín Rullas, Patricia Casado Castro, Florence Leroux, Catherine Piveteau, Mehdi Kiass, Vanessa Mathys, Karine Soetaert, Véronique Megalizzi, Abdalkarim Tanina, René Wintjens, Rudy Antoine, Priscille M Brodin, Vincent Delorme, Martin Moune, Kamel Djaout, Stéphanie Slupek, Christian Kemmer, Marc Gitzinger, Lluis Ballell, Alfonso Mendoza-Losana, Sergio Lociuro, Benoit Déprez, David Barros Aguirre, Modesto J Remuiñán, Nicolas Willand, Alain R Baulard
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis. Science translational medicine 14 (643) (2022)
Ben S Gold, Jun Zhang, Landys Lopez Quezada, Julia Roberts, Yan Ling, Madeleine Wood, Wasima Shinwari, Laurent Goullieux, Christine Roubert, Laurent Fraisse, Eric Bacqué, Sophie Lagrange, Bruno Filoche-Rommé, Michal Vieth, Philip A Hipskind, Louis N Jungheim, Jeffrey Aubé, Sarah M Scarry, Stacey L McDonald, Kelin Li, Andrew Perkowski, Quyen Nguyen, Veronique Anne Dartois, Matthew Zimmerman, David B Olsen, Katherine Young, Shilah Bonnett, Douglas Joerss, Tanya Parish, Helena I M Boshoff, Kriti Arora, Clifton E Barry, Laura Guijarro, Sara Anca, Joaquín Rullas, Beatriz Rodríguez-Salguero, Maria S Martínez-Martínez, Esther Porras-De Francisco, Mónica Cacho, David Barros Aguirre, Paul W Smith, Steven J Berthel, Carl Nathan, Robert H Bates
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions. ACS infectious diseases 8 (3) (2022)
Eric L Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, Beatriz Urones, Jorge Esquivias, Heena Soni, Rokeya Tasneen, Sandeep Tyagi, Si-Yang Li, Paul J Converse, Helena I Boshoff, Gregory Thomas Robertson, Gurdyal S Besra, Katherine A Abrahams, Anna M Upton, Khisimuzi Mdluli, Gary W Boyle, Sam Turner, Nader Fotouhi, Nicholas C Cammack, Juan Miguel Siles, Marta Alonso, Jaime Escribano, Joel Lelievre, Joaquin Rullas-Trincado, Esther Pérez-Herrán, Robert H Bates, Gareth Maher-Edwards, David Barros Aguirre, Lluís Ballell, Elena Jiménez
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrobial agents and chemotherapy 66 (6) (2022)
Uday S Ganapathy, Rubén González Del Río, Mónica Cacho-Izquierdo, Fátima Ortega, Joël Lelièvre, David Barros Aguirre, Wassihun Wedajo Aragaw, Matthew D Zimmerman, Marissa Lindman, Veronique Anne Dartois, Martin Gengenbacher, Thomas Dick
A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrobial agents and chemotherapy 65 (12) (2021)
Uday S Ganapathy, Rubén González Del Rio, Mónica Cacho-Izquierdo, Fátima Ortega, Joël Lelièvre, David Barros Aguirre, Marissa Lindman, Veronique Anne Dartois, Martin Gengenbacher, Thomas Dick
A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity. Antimicrobial agents and chemotherapy (2021)
Abraham L Moure, Gagandeep Narula, Flavia Sorrentino, Adama Bojang, Clement K M Tsui, Carine Sao Emani, Esther Porras-De Francisco, Beatriz Díaz, María José Rebollo-López, Pedro Alfonso Torres-Gómez, Eva María López-Román, Isabel Camino, Patricia Casado Castro, Laura Guijarro López, Fátima Ortega, Lluis Ballell, David Barros Aguirre, Modesto Remuiñán Blanco, Yossef Av-Gay
MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis. Journal of medicinal chemistry 63 (9) (2020)
Olga Balabon, Eleni Pitta, Maciej K Rogacki, Eugenia Meiler, Ruth Casanueva, Laura Guijarro, Sophie Huss, Eva Maria Lopez-Roman, Ángel Santos-Villarejo, Koen Augustyns, Lluis Ballell, David Barros Aguirre, Robert H Bates, Fraser Cunningham, Mónica Cacho, Pieter Van Der Veken
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors. Journal of medicinal chemistry 63 (10) (2020)
David Tenero, Geo Derimanov, Alex Carlton, John Tonkyn, Matt Davies, Simon Cozens, Stephanie Gresham, Alison Gaudion, Adeep Puri, Morris Muliaditan, Joaquin Rullas-Trincado, Alfonso Mendoza-Losana, Andrew Skingsley, David Barros Aguirre
First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. Antimicrobial agents and chemotherapy 63 (8) (2019)
Maciej K Rogacki, Eleni Pitta, Olga Balabon, Sophie Huss, Eva Maria Lopez-Roman, Argyrides Argyrou, Delia Blanco-Ruano, Monica Cacho, Christophe M L Vande Velde, Koen Augustyns, Lluis Ballell, David Barros Aguirre, Robert H Bates, Fraser Cunningham, Pieter Van Der Veken
Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. Journal of medicinal chemistry 61 (24) (2018)
Xianfeng Li, Vincent Hernandez, Fernando L Rock, Wai Choi, Yvonne S L Mak, Manisha Mohan, Weimin Mao, Yasheen Zhou, Eric E Easom, Jacob J Plattner, Wuxin Zou, Esther Pérez-Herrán, Ilaria Giordano, Alfonso Mendoza-Losana, Carlos Alemparte, Joaquín Rullas, Iñigo Angulo-Barturen, Sabrinia Crouch, Fátima Ortega, David Barros Aguirre, M R K Alley
Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). Journal of medicinal chemistry 60 (19) (2017)

David Barros Aguirre.css-eqlu8i{font-size:small;padding-left:4px;} (David Barros-Aguirre, David Barros)

Publication Activity (10 Years)

Top Topics

Top Venues

David Barros Aguirre (David Barros-Aguirre, David Barros)